“As the first therapy with a novel mechanism of action to be approved for CIDP patients in more than 30 years, this approval is an extremely important step towards addressing the unmet needs of patients with this debilitating condition and further signals argenx’s commitment to bring innovative therapeutic options to Australian patients,” said Kathryn Evans, Australia General Manager for argenx. …
New treatment milestone offers fresh hope for Australians living with CIDP
March 30, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
Can GLP-1s be more transformative than AI - one person believes they already are
July 14, 2026 - - Latest News -
The age-old argument for supermarket pharmacies misses the point, and the risks
July 14, 2026 - - Latest News -
Pharmacy Guild rejects Grattan Institute report, describing community pharmacies as essential health providers
July 13, 2026 - - Latest News -
Immutep cancer candidate shows strong median survival in lung cancer as company consider conflicting trial results
July 13, 2026 - - Australian Biotech -
OncoSil Medical establishes scalable Australian production after successful manufacturing validation
July 13, 2026 - - Australian Biotech -
SCENESSE gains Canadian approval offering long term protection for patients with rare disorder
July 13, 2026 - - Australian Biotech -
Patrys and Yale agree revenue share to advance deoxymab platform
July 13, 2026 - - Australian Biotech